D. Ross Camidge, MD, PhD, University of Colorado Anschutz Medical Campus (IMAGE)

University of Colorado Anschutz

D. Ross Camidge, MD, PhD, University of Colorado Anschutz Medical Campus

Caption

D. Ross Camidge, MD, PhD, and colleagues report at ASCO 2017 and publish in NEJM results of ALEX trial showing that 2nd generation ALK-inhibitor alectinib may outperform current standard-of-care, crizotinib.

Credit

University of Colorado Cancer Center

Usage Restrictions

With attribution

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.